Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Hansa Biopharma AB is a biopharmaceutical company headquartered in Lund, Sweden, operating within the healthcare industry. The company specializes in developing immunomodulatory enzyme technology to treat rare immunological conditions. Its leading product, Idefirix, is designed to enable kidney transplants in highly sensitized patients by cleaving immunoglobulin G antibodies. Hansa Biopharma's strategic focus includes expanding its technology platform and gaining regulatory approvals internationally. The company's innovative approach in enzyme-based therapies positions it to address unmet medical needs in transplantation and autoimmunity.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Hansa Biopharma ABJohnson & Johnson
Last price
kr 46.64$283.52
Currency
SEK
USD
kr 4.6B$675B
-42.59
-kr 7.71$6.58
-0.21
0$5.28
01.91%
Sector
HealthHealth
Employees
131138,200
Ticker
Skr HNSA$JNJ
Primary listing
XSTONYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in SkrHNSA or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.